Perindopril erbuminePerindopril erbumine
MedChemExpress (MCE)
HY-B0130A
107133-36-8
Perindopril tert-butylamine salt
S-9490 erbumine
99.98%
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months
-20°C, 1 month (sealed storage, away from moisture)
Room temperature in continental US
may vary elsewhere.
Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NF-κB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure.
Perindopril erbumine (1 μM, 24 h) ameliorats gliosis and blunts decrease induced by LPS (HY-D1056) in AT2R expression in Rat astrocytoma cell line (C6) and murine microglial cell line (BV2)[1]. Perindopril erbumine (1 μM, 24 h) prevents IκBα degradation, NF-кB nuclear translocation and STAT3 activation induced by LPS (HY-D1056) in C6 and BV2[1]. Perindopril erbumine (1 μM, 24 h) ameliorats the imbalance in the release of inflammatory cytokine and blunts the aberrant ROS production and the nitrite release induced by LPS (HY-D1056) in C6 and BV2[1].
Perindopril erbumine (0.1 mg/kg, Oral gavage, once a day for five consecutive days) prevents LPS-induced neuroinflammation in rats[1]. Perindopril erbumine (0.42 mg/kg, Oral, once a day for 4 weeks) with Huangqi-Danshen decoction (HDD) (4.7 g/kg, Oral, once a day for 4 weeks) attenuates adenine(HY-B0152)-induced Chronic kidney disease (CKD) in rats[2]. Perindopril erbumine (0.4-1.5 mg/kg, Oral, once a day for 4-24 weeks) has a persistent effect on blood pressure in spontaneously hypertensive rats (SHR)[4].
SIRT3 STAT3
| | | |
| | | | | |
[1]. Bhat S A, et al. Angiotensin receptor blockade modulates NFκB and STAT3 signaling and inhibits glial activation and neuroinflammation better than angiotensin-converting enzyme inhibition [J]. Molecular neurobiology, 2016, 53: 6950-6967. [Content Brief]
[2]. Wei X, et al. Combination of perindopril erbumine and huangqi-danshen decoction protects against chronic kidney disease via sirtuin3/mitochondrial dynamics pathway [J]. Evidence-Based Complementary and Alternative Medicine, 2022, 2022. [Content Brief]
[3]. Afonso T, et al. Pharmacodynamic evaluation of 4 angiotensin‐converting enzyme inhibitors in healthy adult horses [J]. Journal of veterinary internal medicine, 2013, 27(5): 1185-1192. [Content Brief]
[4]. Thybo N K, et al. Dose-dependent effects of perindopril on blood pressure and small-artery structure [J]. Hypertension, 1994, 23(5): 659-666. [Content Brief]